NCT00834444已完成1 期
A Single Dose, Comparative Bioavailability Study of Two Formulations of Famciclovir 500 mg Tablets Under Non-Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Cmax = Maximum Observed Concentration.
研究概览
简要总结
The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions.
详细描述
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects selected for this study will be at least 18 years of age.
- •Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
- •Each female subject will be give a serum pregnancy test as part of the pre-screening process.
- •Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements.
- •Clinical laboratory measurements will include the following:
- •Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell count (with differential).
- •Clinical Chemistry: creatinine, BUN, glucose, SGOT/AST, SGPT/ALT, bilirubin, and alkaline phosphatase.
- •Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells.
- •HIV Screen: pre-study only.
- •Hepatitis-B, C Screen: pre-study only.
- •Drugs of Abuse Screen: pre-study and at check-in each study period.
- •Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.
排除标准
- •Subjects with a history of alcoholism or drug addiction (during past 2 years), or serious gastrointestinal, renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
- •Subjects whose clinical laboratory test values are outside the normal range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
- •Subjects who have a history of allergic responses to the class of drug being tested should be excluded form the study.
- •All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.
- •Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
- •Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
- •Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate. Subjects who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study dosing, or used oral hormonal contraceptives within 14 days before dosing will not be allowed to participate.
- •All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study.
研究组 & 干预措施
1
Experimental
干预措施: Famciclovir 500 mg Tablets (Drug)
2
Active Comparator
干预措施: Famvir® 500 mg Tablets (Drug)
结局指标
主要结局
Cmax = Maximum Observed Concentration.
时间窗: Blood samples collected over a 16 hour period.
Bioequivalence based on Cmax.
AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)
时间窗: Blood samples collected over a 16 hour period.
Bioequivalence based on AUC0-t.
AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.
时间窗: Blood samples collected over a 16 hour period.
Bioequivalence based on AUC0-inf.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Famciclovir 500 mg Tablets Under Fasting ConditionsHealthyNCT00834431Teva Pharmaceuticals USA36
已完成
不适用
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed ConditionsHerpesNCT01321502Roxane Laboratories31
已完成
不适用
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted ConditionsHerpesNCT01321515Roxane Laboratories36
已完成
1 期
Pharmacokinetics of Faldaprevir of Soft CapsuleHealthyNCT01821937Boehringer Ingelheim25
已完成
1 期
Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting StateHealthyNCT00648960Mylan Pharmaceuticals Inc64